Proton Beam Therapy versus Radiofrequency Ablation for Patients with Treatment-Naïve Single Hepatocellular Carcinoma: A Propensity Score Analysis.
Journal Information
Full Title: Liver Cancer
Abbreviation: Liver Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Gastroenterology & Hepatology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of Interest Statement Ryosuke Tateishi has received lecture fees from STARmed Co., Ltd., Medtronic plc, Merk Sharp & Dohme, Chugai Pharmaceutical Co., Ltd., Bristol-Meyers Squibb, Giliad Sciences, AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Eisai Co., Ltd., and Bayer Co., Ltd. Hayato Nakagawa has received lecture fees from Bristol-Meyers Squibb, Giliad Sciences, AbbVie GK, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd. Yoshinari Asaoka has received consultation fees from Eisai Co., Ltd. Shuichiro Shiina has received lecture fees from Starmed Co., Ltd., Medtronic plc, Japan Lifeline Co., Ltd., Canon Medical Co., Ltd., Shionogi Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Giliad Sciences, AbbVie GK, Eisai Co., Ltd., and Bayer Co., Ltd. Kazuhiko Koike has received lecture fees from Eisai, Bayer, MSD, Abbvie, Gilead, and Otsuka Pharmaceutical Co., Ltd."
"This research was supported by AMED under grant number JP18ck0106210 and the Health, Labour and Welfare Policy Research Grants from the Ministry of Health, Labour, and Welfare of Japan (Policy Research for Hepatitis Measures [H30-Kansei-Shitei-003])."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025